Catalyst Pharmaceuticals Reports Strong 2025 Financials, Driven by AGAMREE Launch & FIRDAPSE Patent Wins

summarizeSummary

Catalyst Pharmaceuticals reported strong 2025 financial results, fueled by the successful launch of AGAMREE and favorable patent settlements for FIRDAPSE, alongside a new share repurchase program.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported total revenues of $589.0 million and net income of $214.3 million for fiscal year 2025, representing significant year-over-year growth.

• Successful AGAMREE Launch & Expansion

  AGAMREE generated $117.1 million in net product revenue in its first full year of commercialization (launched March 2024) and received regulatory approvals in Canada and Switzerland, achieving a $12.5 million sales-based milestone.

• Favorable FIRDAPSE Patent Settlements

  Secured market entry protection for FIRDAPSE until February 25, 2035, through patent settlements with Teva and Lupin, despite ongoing litigation with Hetero. FIRDAPSE was also included in NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC).

• New Share Repurchase Program

  The Board authorized a new $200 million share repurchase program in October 2025, with $39.9 million in shares already repurchased as of February 23, 2026.

auto_awesomeAnalysis

Catalyst Pharmaceuticals delivered robust financial results for fiscal year 2025, with significant increases in both total revenue and net income. The successful commercial launch of AGAMREE for Duchenne muscular dystrophy (DMD) was a major growth driver, generating substantial revenue in its first full year and expanding internationally with approvals in Canada and Switzerland. Crucially, the company secured long-term market exclusivity for its lead product, FIRDAPSE, through favorable patent settlements with key generic manufacturers, extending protection until 2035. The initiation of a new $200 million share repurchase program further signals management's confidence in the company's financial health and future prospects. While FYCOMPA revenue declined due to generic competition, this was an anticipated event and is being managed with the cessation of active marketing.